ICCG High Dose Study

Disease site: Breast Cancer

Treatment Modality: Chemotherapy

Status: In active follow-up

The ICCG High Dose Study is a randomised trial evaluating the role of high dose chemotherapy in patients with primary breast cancer. The control arm of the study was based on a conventional 5- fluorouracil–epirubicin-cyclophosphamide (-HDT) regimen and the 'high dose therapy regimen' was designed to consist of three cycles of FEC chemotherapy followed by the high dose cyclophosphamide - thiotepa - carboplatin i.e. CTCb regimen (+HDT). To be eligible, patients had to be free of overt metastatic disease, be less than or equal to 60 years of age with 4 or more histollogically involved lymph nodes.

Recruitment to this study closed on 28/09/02 (281 patients) and active follow up continues.

This is an International Collaborative Cancer Group (ICCG) trial (C/10/92).

Publication

Coombes, Vigushin, Kanfer et al, 2003 ASCO Annual Meeting. Randomised Trial of High Dose Therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes.